News
04-15-2010, 03:22 AM
Pfizer Oncology announced today that it will present new data from the company's pipeline, including two novel, dual PI3K/mTOR inhibitors (PF-04691502 and PKI-587, also known as PF-05212384); crizotinib (PF-02341066), an ALK inhibitor that also inhibits c-MET; and PF-04605412, an anti-?5?1 inhibitor.
More... (http://www.news-medical.net/news/20100415/New-data-from-Pfizer-Oncologys-pipeline-to-be-presented-at-AACR-2010.aspx)
More... (http://www.news-medical.net/news/20100415/New-data-from-Pfizer-Oncologys-pipeline-to-be-presented-at-AACR-2010.aspx)